Compare Abeona Therapeutics Inc (ABEO) vs Gogoro Inc (GGR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Gogoro Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Gogoro Inc trades at $3.9 (market cap $76.99M). The key difference: Abeona Therapeutics Inc is far larger — about 4.8× Gogoro Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | GGR | |
|---|---|---|
Market Cap | $373.32M | $76.99M |
Sector | Health | Technology |
52-Week High | $7.23 | $7.89 |
52-Week Low | $4.17 | $2.74 |
Enterprise Value | $228.22M | $379.44M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GGR trades at $3.94, down 0.51% today, with a bearish technical signal and negative profitability. The company reported a net loss of $79.97 million on $281.48 million revenue for 2025, though operating cash flow improved to $35.90 million. Recent news highlights a private placement and Q1 2026 results emphasizing margin improvements and growth initiatives.
The outlook remains challenging due to persistent losses and negative ROE, but low valuation multiples and projected cash flow improvements offer potential upside if execution improves. Key risks include sustained unprofitability and competitive pressures in the mobility sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
